Status:
RECRUITING
Infusion Set Replacement Intervals for Critically Ill Patients
Lead Sponsor:
Zhongnan Hospital
Conditions:
Critical Illness
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study aimed to evaluate the efficacy of 24-hour versus 96-hour infusion set replacement to prevent central line-associated bloodstream infection (CLABSI) in critically ill adults with central ven...
Detailed Description
Up to 70% of patients in acute care hospitals need a central venous access, and the latter is also widely used in other clinical settings. However, the central venous access usually remains associated...
Eligibility Criteria
Inclusion
- Age 18 years or older
- Able to provide informed consent
- Expected length of stay (LOS) \> 96 hours in intensive care unit (ICU)
- Need for treatment with central venous access device
- The central venous access device is expected to remain in place for at least 96 hours, with infusion set attached
Exclusion
- Those who with a bloodstream infection within the previous 48 hours after ICU admission
- Those who have their vascular access device actually removed within 96 hours after ICU admission
- Those who have participated in other clinical studies within the 2 months
Key Trial Info
Start Date :
May 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
1240 Patients enrolled
Trial Details
Trial ID
NCT05359601
Start Date
May 15 2022
End Date
June 30 2026
Last Update
December 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China, 430070